Researchers at The Scripps Research Institute discovered that cells instruct proteins to form aggregates to protect them from toxicity associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The research team, led by Claudio Joazeiro, associate professor of cell and molecular biology at Scripps, identified an enzyme that…
Scripps Research Institute (TSRI) scientists have identified a new player in the ribosome-associated quality control complex that “tags” abnormal proteins, prompting them to aggregate and form clumps. This study, for a first time, shows that proteins can be marked for aggregation, and may constitute a new molecular pathway underlying neurodegenerative diseases such…
The ALS Association, together with partner Prize4Life, has announced the First Phase winners of The ALS Assistive Technology Challenge, which now enters its Prize Phase, where $400,000 will be awarded for the development of flexible, accessible technology to help people with amyotrophic lateral sclerosis (ALS) communicate better.
Matt Belina, US Navy pilot was diagnosed with amyotrophic lateral sclerosis (ALS) in 2012. He and his wife are now actively trying to fight the barriers the FDA’s lack of approvals raise and prevent him from having access to experimental drugs he believes might save his life. Learn more…
German researchers have identified a new gene — called NEK1 — that appears to be responsible for familial amyotrophic lateral sclerosis (ALS). Loss of function mutations in the gene were more common in ALS patients than in healthy controls, according to findings published in the journal Brain. Familial ALS…
Jen and Pat Quinn, alumni from Iona College, were distinguished during the halftime at the Iona College Men’s basketball game versus Quinnipiac for their fight against amyotrophic lateral sclerosis (ALS). Video by SALRADIO. Learn more about ALS here: https://bit.ly/1RmVMwo…
OptiKey is a free, assistive on-screen keyboard software for computers on the Windows operating system. It is designed to be used with a low cost eye-tracking device to enable speech and keyboard and mouse control to people with motor and speech limitations, such as amyotrophic lateral sclerosis (ALS) or…
Last week’s hot topic on ALS was an article titled Biohaven’s ALS Drug Candidate BHV-0223 Receives Positive FDA Feedback written by Magdalena Kegel. The article is focused on the recently announcement that Portage Biotech and Biohaven Pharmaceuticals have received positive feedback from the U.S.
Motor neurodegeneration in amyotrophic lateral sclerosis (ALS) can begin in axons at neuromuscular junctions and later spread to the cell body in the spinal cord, in a phenomenon known as the “dying back” hypothesis. Proteins involved in axonal regeneration may, for this reason, represent a potential therapeutic target in ALS. A research team from Germany found…
Portage Biotech and Biohaven Pharmaceuticals recently announced they have received positive feedback from the U.S. Food and Drug Administration (FDA) on their Pre-Investigational New Drug Application (PIND) interaction regarding Biohaven’s investigative drug BHV-0223, intended for treatment of amyotrophic lateral sclerosis (ALS). BHV-0223 is the glutamate modulating compound riluzole, contained in the tablet…
